IDEXX Laboratories (IDXX) stock soared 8.30% in pre-market trading on Monday following the release of its impressive second-quarter 2025 results and an upward revision of its full-year guidance. The company, a leader in pet healthcare innovation, reported better-than-expected earnings and revenue, demonstrating robust growth across its business segments.

For Q2 2025, IDEXX reported earnings per share (EPS) of $3.63, significantly surpassing the FactSet analyst estimate of $3.30. Revenue for the quarter reached $1.109 billion, exceeding the expected $1.067 billion. The company's performance was driven by strong growth in its Companion Animal Group (CAG) segment, with CAG Diagnostics recurring revenue increasing by 9% as reported and 7% organically. Notably, IDEXX saw a remarkable 66% growth in CAG Diagnostics instrument revenues, bolstered by the success of recent innovations like the IDEXX InVue Dx™ and IDEXX Cancer Dx™.

In light of these strong results, IDEXX has raised its full-year 2025 guidance. The company now expects revenue in the range of $4.205 billion to $4.280 billion, reflecting a growth of 7.7% to 9.7%. This outlook surpasses the previous FactSet consensus estimate of $4.15 billion. Additionally, IDEXX increased its EPS guidance to a range of $12.40 to $12.76, up from the prior projection of $11.93 to $12.43 and above the FactSet estimate of $12.21. The improved outlook, coupled with the company's solid Q2 performance and continued innovation in pet diagnostics, has clearly resonated with investors, driving the significant pre-market stock surge.